Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prasad Mathew

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Data in Brief|September 9, 2020
Pharmacokinetic characteristics of the triple inactivated plasma-derived Kedrion FIX concentrate: data from the KB037 clinical trialMassimo Morfini, Chiara Guarnieri, Roberta Macchia, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|January 7, 2014
Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registryJan Blatný, Prasad Mathew, Paul Monagle, et al.
Journal of Environmental Biology|April 5, 2007
Glutathione and associated enzymes in toxic cataractogenesis-selenite modelJoe Prasad Mathew, Priya Joseph, V C Thomas, et al.
Transfusion|January 9, 2007
How we manage requests for recombinant factor VIIa (NovoSeven)Prasad Mathew, Toby L Simon, Kristin E Hunt, et al.
Clinics in Laboratory Medicine|August 12, 2009
The laboratory approach to inherited and acquired coagulation factor deficienciesBenjamin L Wagenman, Kelly T Townsend, Prasad Mathew, et al.
The American Surgeon|August 11, 2005
Recombinant activated factor VII as an adjunct to packing for liver injury with hepatic venous disruptionJoachim Chino, David Paolini, Anh Tran, et al.
Medical and Pediatric Oncology|July 13, 2002
Cellular neurothekeoma of the chest wallJeffery Hanrahan, Marcia Wills, Jami Frost, et al.
Current Medical Research and Opinion|January 6, 2006
Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitorsAshish V Joshi, Jennifer M Stephens, Vicki Munro, et al.
Thrombosis and Haemostasis|January 22, 2016
Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levelsRolf Ljung, Kathelijn Fischer, Manuel Carcao, et al.
Advances in Hematology|September 11, 2015
Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance StudiesThomas J Humphries, Stephan Rauchensteiner, Claudia Tückmantel, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Data in Brief|September 9, 2020
Pharmacokinetic characteristics of the triple inactivated plasma-derived Kedrion FIX concentrate: data from the KB037 clinical trialMassimo Morfini, Chiara Guarnieri, Roberta Macchia, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|January 7, 2014
Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registryJan Blatný, Prasad Mathew, Paul Monagle, et al.
Journal of Environmental Biology|April 5, 2007
Glutathione and associated enzymes in toxic cataractogenesis-selenite modelJoe Prasad Mathew, Priya Joseph, V C Thomas, et al.
Transfusion|January 9, 2007
How we manage requests for recombinant factor VIIa (NovoSeven)Prasad Mathew, Toby L Simon, Kristin E Hunt, et al.
Clinics in Laboratory Medicine|August 12, 2009
The laboratory approach to inherited and acquired coagulation factor deficienciesBenjamin L Wagenman, Kelly T Townsend, Prasad Mathew, et al.
The American Surgeon|August 11, 2005
Recombinant activated factor VII as an adjunct to packing for liver injury with hepatic venous disruptionJoachim Chino, David Paolini, Anh Tran, et al.
Medical and Pediatric Oncology|July 13, 2002
Cellular neurothekeoma of the chest wallJeffery Hanrahan, Marcia Wills, Jami Frost, et al.
Current Medical Research and Opinion|January 6, 2006
Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitorsAshish V Joshi, Jennifer M Stephens, Vicki Munro, et al.
Thrombosis and Haemostasis|January 22, 2016
Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levelsRolf Ljung, Kathelijn Fischer, Manuel Carcao, et al.
Advances in Hematology|September 11, 2015
Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance StudiesThomas J Humphries, Stephan Rauchensteiner, Claudia Tückmantel, et al.
Pageof 5